Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López-Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Ribera JM, et al. Among authors: calbacho m. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. Blood. 2021. PMID: 33150388 Free article. Clinical Trial.
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Infante MS, Salmanton-García J, Fernández-Cruz A, Marchesi F, Jaksic O, Weinbergerová B, Besson C, Duarte RF, Itri F, Valković T, Szotkovski T, Busca A, Guidetti A, Glenthøj A, Collins GP, Bonuomo V, Sili U, Seval GC, Machado M, Cordoba R, Blennow O, Abu-Zeinah G, Lamure S, Kulasekararaj A, Falces-Romero I, Cattaneo C, Van Doesum J, Piukovics K, Omrani AS, Magliano G, Ledoux MP, de Ramon C, Cabirta A, Verga L, López-García A, Da Silva MG, Stojanoski Z, Meers S, Lahmer T, Martín-Pérez S, Dávila-Vals J, Van Praet J, Samarkos M, Bilgin YM, Karlsson LK, Batinić J, Nordlander A, Schönlein M, Hoenigl M, Ráčil Z, Mladenović M, Hanakova M, Zambrotta GPM, De Jonge N, Adžić-Vukičević T, Nunes-Rodrigues R, Prezioso L, Navrátil M, Marchetti M, Cuccaro A, Calbacho M, Giordano A, Cornely OA, Hernández-Rivas JÁ, Pagano L. Infante MS, et al. Among authors: calbacho m. Front Oncol. 2022 Oct 3;12:992137. doi: 10.3389/fonc.2022.992137. eCollection 2022. Front Oncol. 2022. PMID: 36276116 Free PMC article.
Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
Ribera JM, García O, Fernández-Abellán P, Lavilla E, Bernal MT, González-Campos J, Brunet S, Monteserín MC, Montesinos P, Sarrá J, Calbacho M, Alvarez-Larrán A, Tormo M, Oriol A; PETHEMA Group. Ribera JM, et al. Among authors: calbacho m. Br J Haematol. 2012 Nov;159(4):485-8. doi: 10.1111/bjh.12043. Epub 2012 Sep 12. Br J Haematol. 2012. PMID: 22966847 Free article. Clinical Trial. No abstract available.
Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy.
Kelleher N, Gallardo D, González-Campos J, Hernández-Rivas JM, Montesinos P, Sarrá J, Gil C, Barba P, Guàrdia R, Brunet S, Bernal T, Martínez MP, Abella E, Bermúdez A, Sánchez-Delgado M, Antònia C, Gayoso J, Calbacho M, Ribera JM; Pethema Group, Spanish Society of Hematology. Kelleher N, et al. Among authors: calbacho m. Leuk Lymphoma. 2016;57(1):86-91. doi: 10.3109/10428194.2015.1040013. Epub 2015 May 12. Leuk Lymphoma. 2016. PMID: 25860236
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.
Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: calbacho m. Leuk Res. 2016 Feb;41:12-20. doi: 10.1016/j.leukres.2015.11.012. Epub 2015 Dec 2. Leuk Res. 2016. PMID: 26686475 Clinical Trial.
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: calbacho m. Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29165013 Clinical Trial.
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E; PETHEMA Group. Ribera JM, et al. Among authors: calbacho m. Leuk Res. 2018 May;68:79-84. doi: 10.1016/j.leukres.2018.03.010. Epub 2018 Mar 19. Leuk Res. 2018. PMID: 29574396
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.
Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sanchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliu E, Orfao A, Ribera JM. Barba P, et al. Among authors: calbacho m. Eur J Haematol. 2019 Jan;102(1):79-86. doi: 10.1111/ejh.13178. Epub 2018 Nov 22. Eur J Haematol. 2019. PMID: 30267597 Clinical Trial.
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
Ribera JM, Morgades M, Montesinos P, Tormo M, Martínez-Carballeira D, González-Campos J, Gil C, Barba P, García-Boyero R, Coll R, Pedreño M, Ribera J, Mercadal S, Vives S, Novo A, Genescà E, Hernández-Rivas JM, Bergua J, Amigo ML, Vall-Llovera F, Martínez-Sánchez P, Calbacho M, García-Cadenas I, Garcia-Guiñon A, Sánchez-Sánchez MJ, Cervera M, Feliu E, Orfao A; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: calbacho m. Cancer Med. 2020 Apr;9(7):2317-2329. doi: 10.1002/cam4.2814. Epub 2020 Feb 5. Cancer Med. 2020. PMID: 32022463 Free PMC article.
52 results